DrugPatentWatch Database Preview

Details for Patent: 6,096,342

« Back to Dashboard

Summary for Patent: 6,096,342

Title:	Dosage forms of risedronate
Abstract:	The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.
Inventor(s):	Dansereau; Richard John (Sherburne, NY), Mosher; Russell Youker (Norwich, NY), Axelrod; Douglas Wayne (Norwich, NY), Sietsema; William Kendall (Norwich, NY)
Assignee:	The Procter & Gamble Company (Mason, OH)
Application Number:	09/303,466
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,096,342
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 6,096,342

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,096,342

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	195075
Australia	3060492
Australia	661080